WOODBURY, Minnesota — The early-stage pharmaceutical company CNS Therapeutics has raised $7 million, according to a filing with the Securities and Exchange Commission.
Not much is known about the 2-year-old company and CNS President John Foster won’t share development plans publicly. Foster is the former senior vice president of commercialization of Restore Medical, the sleep disorder device company that Medtronic purchased in 2008 for $29 million. He’s also worked at Medtronic and Genentech.
Foster’s background and the company’s name (CNS is short for central nervous system) are the only publicly available clues about the business. Foster said he hopes to share more about the company sometime next year after it finalizes its intellectual property rights.
Previous investors InterWest Partners and Thomas McNerney Partners led this round, Foster said. The company raised $6 million last year, according to filing with the SEC.
